Volunteer for COVID-19 Clinical Trials

NIAID is conducting and supporting clinical trials evaluating therapies and vaccine candidates against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), as well as studies of people who have recovered from infection.

Featured COVID-19 Studies

Ongoing NIAID-supported COVID-19 Studies

Below is a selection of ongoing NIAID-supported studies. A frequently updated, comprehensive list of all COVID-19 clinical trials can be found on ClinicalTrials.gov

Select from the options below based on which health category you fall under to find COVID-19 clinical study volunteer opportunities appropriate for you.

To qualify, volunteers must not have had a positive COVID-19 diagnostic test at any time in the past, even if you did not have any symptoms. If you have had a positive COVID-19 test in the past, you may qualify for studies that are seeking volunteers who have recovered from COVID-19.

These studies are seeking volunteers who may be exposed to SARS-CoV-2, the virus that causes COVID-19, in their everyday activities:

ENSEMBLE Study with Janssen’s Ad26.COV2.S Investigational Vaccine

  • Study Goal: The trial is designed to evaluate if the investigational Janssen COVID-19 vaccine (JNJ-78436725) can prevent symptomatic COVID-19 after a single dose.
  • Locations: Clinical research sites are distributed throughout the United States. Fill out the volunteer questionnaire to find out if you qualify and you will be matched with the appropriate research site.
  • Official Study Title: A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)

Vaccine and Monoclonal Antibody Studies for the Prevention of COVID-19

  • Study Goal: The COVID-19 Prevention Network (CoVPN) is conducting studies to find safe and effective vaccines and monoclonal antibodies for (SARS-CoV-2), the virus that causes COVID-19.
  • Locations: Clinical research sites are located throughout the United States. Fill out the volunteer questionnaire to find out if you qualify, and you will be matched with the appropriate research site.

Vaccine Study To Evaluate If mRNA-1273 Prevents COVID-19 in Adults

  • Study Goal: The mRNA-1273 vaccine is being developed to prevent COVID-19. The purpose of this study is to test Moderna’s vaccine candidate to see if it can prevent illness if people are exposed to the SARS-CoV-2 virus in their everyday lives. The mRNA-1273 vaccine is not made from the SARS-CoV-2 virus.
  • Locations: Clinical research sites are distributed throughout the United States. Fill out the volunteer questionnaire to find out if you qualify and you will be matched with the appropriate research site.
  • Official Study Title: A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Pandemic Blood Sampling Study

  • Study Goal: A study at the NIH Clinical Center in Bethesda, Maryland, aims to determine how many adults in the United States without a confirmed history of infection with SARS-CoV-2, the virus that causes COVID-19, have antibodies to the virus. The presence of antibodies in the blood indicates a prior infection. In this “serosurvey,” researchers will collect and analyze blood samples from as many as 10,000 volunteers to provide critical data for epidemiological models that look into how an illness spreads in the community. The results will help shed light on the extent to which the virus has spread undetected in the United States and provide insights into which communities and populations are most affected.
  • Locations: Samples can be taken in person at the NIH in Bethesda, Maryland, or home sample kits may be mailed if you qualify to volunteer.
  • Official Study Title: SARS-COV2 Pandemic Serosurvey and Blood Sampling

Working or living with others who have COVID-19 puts you at high risk of exposure. If you live with someone who has tested positive for SARS-CoV-2, the virus that causes COVID-19, or you work in a medical or assisted living facility where you are caring for COVID-19 patients, you may qualify for these studies.

COVID-19 Antibody Treatment Study for Preventing SARS-CoV-2 Infection in Nursing Home Residents and Staff

  • Study Goal: This trial will assess whether LY-CoV555, a potential COVID-19 antibody treatment, can prevent SARS-CoV-2 infection among people at high risk of exposure due to residing or working in skilled nursing or assisted living facilities.
  • Locations: Clinical research sites are distributed throughout the United States. Fill out the volunteer questionnaire to find out if you qualify and you will be matched with the appropriate research site.
  • Official Study Title: A Study of LY3819253 (LY-CoV555) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (BLAZE-2)

Monoclonal Antibodies Study for Prevention of SARS CoV-2 Infection in Healthy Adults Who Are Household Contacts to an Individual With a Positive COVID-19 Test

  • Study Goal: This study will evaluate Regeneron’s investigational double monoclonal antibody (mAb) combination, REGN-COV-2, which is designed to bind to two points on the SARS-CoV-2 spike protein and prevent it from entering healthy cells.
  • Locations: Clinical research sites are distributed throughout the United States. Visit the clinical trial registry to find out if you qualify and you will be matched with the appropriate research site.
  • Official Study Title: Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

COVID-19-Recovered Specimen Collection Study

  • Study Goal: The NIAID Vaccine Research Center is looking for volunteers who are fully recovered from confirmed COVID-19 infection to donate blood for a research study. The aim of the study is to further define and understand specific immune responses.
  • Locations: NIH Clinical Center in Bethesda, Maryland
  • Official Study Title: Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies

Study of How COVID-19 Affects Blood Cells and the Immune System

  • Study Goal: A study about how SARS-CoV-2, the virus that causes COVID-19, affects the body, specifically how it affects blood cells and the immune system.
  • Locations: Washington, DC Metro Area
  • Official Study Title: COVID-19–associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
     

Study of Long-Term Medical Problems and Long-Term Immunity After COVID-19 Recovery

  • Study Goal: A study about long-term medical problems experienced by people who recover from COVID-19 and whether people who recover develop long-term immunity to SARS-CoV-2, the virus that causes COVID-19.
  • Locations: The NIH in Bethesda, Maryland
  • Official Study Title: Longitudinal Study of COVID-19 Sequelae and Immunity (RECON_19)

Study of the Immune Response to the Seasonal Influenza Vaccine and How Previous Infection With SARS-CoV-2 May Change That Response

  • Study Goal: This study evaluates the response of the immune system, the part of the body that helps fight infections, to the seasonal influenza vaccine in healthy individuals and also investigates whether prior SARS-CoV-2 infection may change that response.
  • Locations: The NIH in Bethesda, Maryland
  • Official Study Title: Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

These studies are seeking volunteers who have had a confirmed diagnostic test for COVID-19 but are not sick enough to need hospitalization.

Cardiopulmonary Inflammation and Multi-System Imaging During COVID-19 Infection in Asymptomatic and Symptomatic Persons

  • Study Goal: A study to learn how coronavirus affects different organs of the body and the function of the body's immune system.
  • Locations: The NIH in Bethesda, Maryland
  • Official Study Title: Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (COVIDARC19)

Drug Treatment Study of Individuals With Mild COVID-19

  • Study Goal: This research study is about an experimental drug for COVID-19 called NT-I7. We are studying whether the experimental drug is safe for people with COVID-19. We also want to see if it might help treat COVID-19 by supporting the immune system.
  • Locations: The NIH in Bethesda, Maryland
  • Official Study Title: A double-blind, randomized, placebo-controlled, phase 1, single-dose, dose-escalating trial of long-acting recombinant human IL-7 (NT-I7) for COVID-19 (SPESELPIS)

Drug Treatment Study for Outpatients With COVID-19

  • Study Goal: This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. Participants in the study will receive an experimental therapy or a placebo.
  • Locations: See the study page on ClinicalTrials.gov for locations.
  • Official Study Title: Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID or ACTIV-2)

Genetics of COVID-19 Susceptibility and Manifestations

  • Study Goal: The goal of this study is to learn more about the genetic contributions to the severity of disease in COVID-19. We hope to use this information to develop therapies to reduce the severity of symptoms of COVID-19 in some people.
  • Locations: Participants will complete the health survey over the phone. Local participants may come to the NIH Clinical Center for the blood draw, while others may visit their local Quest Lab for the blood draw. For either option, we cover the cost of the blood draw.
  • Official Study Title: Genetics of COVID-19 Susceptibility and Manifestations (COVIDcode)

Study of How COVID-19 Affects Blood Cells and the Immune System

  • Study Goal: A study about how SARS-CoV-2, the virus that causes COVID-19, affects the body, specifically how it affects blood cells and the immune system.
  • Locations: Washington, DC Metro Area
  • Official Study Title: COVID-19–associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
     

These studies are occurring in specific hospitals and seeking volunteers with severe COVID-19. Volunteers will typically be connected to the studies through their medical care providers.

Big Effect Trial (BET) for Finding Promising Treatments of COVID-19

  • Study Goal: The BET-B stage will evaluate the combination of remdesivir with lenzilumab vs remdesivir with a lenzilumab placebo. The primary objective is to evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8-point ordinal scale) at Day 8.
  • Locations: This study will take place in as many as 40 locations in the United States. See the study page on ClinicalTrials.gov for locations.
  • Official Study Title: Big Effect Trial for the Treatment of COVID-19 (ACTIV-5/BET-B)

Drug Treatment for Inpatients With COVID-19

  • Study Goal: This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC.
  • Locations: This study will take place in up to 19 locations in the United States. See the study page on ClinicalTrials.gov for locations.
  • Official Study Title: ACTIV-3 or Therapeutics for Inpatients With COVID-19 (TICO)

Immune Response Tracking in Hospitalized COVID-19 Patients

  • Study Goal: An NIAID-supported study being conducted at 10 research sites across the United States will track the immune responses of people hospitalized with COVID-19.
  • Locations: This study is enrolling only by invitation.
  • Official Study Title: Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)

Inpatient Treatment With Anti-Coronavirus Immunoglobulin

  • Study Goal: This protocol will serve as a platform for assessing treatments for adult patients hospitalized for medical management of COVID-19 without related serious end-organ failure. This trial will compare hyperimmune intravenous immunoglobulin (hIVIG) with matched placebo, when added to standard of care including remdesivir, for preventing further disease progression and mortality related to COVID-19. 
  • Locations: Denver, Colorado and international locations.
  • Official Study Title: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19 (ITAC)

Remdesivir Treatment for Patients Hospitalized With COVID-19

  • Study Goal: This study will evaluate the safety and efficacy of a combination of interferon beta-1a and remdesivir compared to remdesivir alone while patients are hospitalized.
  • Locations: This study will take place in up to 60 locations in the United States. See the study page on ClinicalTrials.gov for locations.
  • Official Study Title: Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

Study of How COVID-19 Affects Blood Cells and the Immune System

  • Study Goal: A study about how SARS-CoV-2, the virus that causes COVID-19, affects the body, specifically how it affects blood cells and the immune system.
  • Locations: Washington, DC Metro Area
  • Official Study Title: COVID-19–associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
Content last reviewed on